
The Finn Lab produces the virus-like particle (VLP) platforms that anchor the Marques Lab's α-Gal vaccine research, and brings deep expertise in bioconjugate and click chemistry to the design of these delivery systems. The two labs have co-authored multiple publications on VLP-carbohydrate conjugation strategies for leishmaniasis and Chagas disease.
This page highlights research partnerships central to the Marques Lab's ongoing work. It will grow as new collaborations develop — check back for updates.